Telix Pharmaceuticals Limited (TLX)
NASDAQ: TLX · Real-Time Price · USD
18.80
-0.42 (-2.19%)
Apr 25, 2025, 4:00 PM EDT - Market closed
Telix Pharmaceuticals Income Statement
Financials in millions AUD. Fiscal year is January - December.
Millions AUD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Revenue | 783.21 | 502.55 | 160.1 | 7.6 | 5.21 | Upgrade
|
| Revenue Growth (YoY) | 55.85% | 213.90% | 2007.64% | 45.71% | 49.58% | Upgrade
|
| Cost of Revenue | 299.26 | 198.03 | 65.17 | 2.55 | 2.02 | Upgrade
|
| Gross Profit | 483.95 | 304.52 | 94.93 | 5.05 | 3.19 | Upgrade
|
| Selling, General & Admin | 207.13 | 124.29 | 87.1 | 46.99 | 24.48 | Upgrade
|
| Research & Development | 194.64 | 128.54 | 81.01 | 34.14 | 23.09 | Upgrade
|
| Other Operating Expenses | 0.29 | -0.19 | 0.93 | - | - | Upgrade
|
| Operating Expenses | 402.05 | 252.63 | 169.03 | 86.3 | 52.44 | Upgrade
|
| Operating Income | 81.9 | 51.89 | -74.11 | -81.25 | -49.25 | Upgrade
|
| Interest Expense | -7.25 | -0.78 | -0.32 | -0.16 | -0.19 | Upgrade
|
| Interest & Investment Income | 10.86 | 1.02 | 0 | - | 0.07 | Upgrade
|
| Currency Exchange Gain (Loss) | 18.71 | -0.97 | -1.12 | 1.7 | -3.94 | Upgrade
|
| Other Non Operating Income (Expenses) | -29.69 | -12.99 | -6.37 | 14.1 | 12.11 | Upgrade
|
| EBT Excluding Unusual Items | 74.53 | 38.17 | -81.92 | -65.61 | -41.21 | Upgrade
|
| Merger & Restructuring Charges | -8.18 | - | - | - | - | Upgrade
|
| Asset Writedown | 0.77 | -0.8 | - | - | - | Upgrade
|
| Other Unusual Items | -11.06 | -34.28 | -16.71 | -14.86 | -6.73 | Upgrade
|
| Pretax Income | 56.06 | 3.09 | -98.62 | -80.47 | -47.94 | Upgrade
|
| Income Tax Expense | 6.14 | -2.12 | 5.46 | 0.05 | -3.05 | Upgrade
|
| Net Income | 49.92 | 5.21 | -104.08 | -80.51 | -44.89 | Upgrade
|
| Net Income to Common | 49.92 | 5.21 | -104.08 | -80.51 | -44.89 | Upgrade
|
| Net Income Growth | 857.95% | - | - | - | - | Upgrade
|
| Shares Outstanding (Basic) | 331 | 319 | 311 | 282 | 257 | Upgrade
|
| Shares Outstanding (Diluted) | 345 | 324 | 311 | 282 | 257 | Upgrade
|
| Shares Change (YoY) | 6.64% | 4.21% | 10.08% | 9.69% | 10.21% | Upgrade
|
| EPS (Basic) | 0.15 | 0.02 | -0.34 | -0.29 | -0.17 | Upgrade
|
| EPS (Diluted) | 0.14 | 0.02 | -0.34 | -0.29 | -0.17 | Upgrade
|
| EPS Growth | 798.14% | - | - | - | - | Upgrade
|
| Free Cash Flow | 14.25 | 14.21 | -71.01 | -60.67 | 1.71 | Upgrade
|
| Free Cash Flow Per Share | 0.04 | 0.04 | -0.23 | -0.21 | 0.01 | Upgrade
|
| Gross Margin | 61.79% | 60.60% | 59.29% | 66.46% | 61.17% | Upgrade
|
| Operating Margin | 10.46% | 10.32% | -46.29% | -1069.60% | -944.81% | Upgrade
|
| Profit Margin | 6.37% | 1.04% | -65.01% | -1059.90% | -861.06% | Upgrade
|
| Free Cash Flow Margin | 1.82% | 2.83% | -44.35% | -798.67% | 32.84% | Upgrade
|
| EBITDA | 87.58 | 57.17 | -69.59 | -76.73 | -44.94 | Upgrade
|
| EBITDA Margin | 11.18% | 11.38% | -43.47% | - | - | Upgrade
|
| D&A For EBITDA | 5.69 | 5.29 | 4.52 | 4.52 | 4.31 | Upgrade
|
| EBIT | 81.9 | 51.89 | -74.11 | -81.25 | -49.25 | Upgrade
|
| EBIT Margin | 10.46% | 10.32% | -46.29% | - | - | Upgrade
|
| Effective Tax Rate | 10.95% | - | - | - | - | Upgrade
|
Updated Feb 20, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.